Purpose: To investigate whether administering cilostazol after treatment for femoropopliteal in-stent restenosis (ISR) can have a positive impact on recurrent ISR (Re-ISR). Methods: The database of a multicenter, retrospective, observational registry was interrogated to identify 338 consecutive patients (mean age 72.3±8.8 years; 148 men) who underwent endovascular therapy for femoropopliteal ISR in 379 limbs from January 2010 to December 2014. Ninety-seven patients (103 limbs) who received cilostazol after the initial stent implantation procedure were excluded. This left 24 ISR patients (30 limbs) who received cilostazol initially after ISR treatment for comparison with 217 ISR patients (246 limbs) who did not receive the drug. The primary endpoint was 2-year Re-ISR after treatment. The secondary endpoints were recurrent target lesion revascularization (Re-TLR) and reocclusion at 2 years. Restenosis was determined by a peak systolic velocity ratio >2.4 on a duplex scan or >50% stenosis on angiography. Results: The mean follow-up was 23.3±15.5 months. At 2 years, freedom from Re-ISR was significantly higher in the cilostazol group than in the no cilostazol group (48.6% vs 32.4%, p=0.047). However, freedom from Re-TLR and reocclusion between the 2 groups did not differ significantly [64.7% vs 53.8% (p=0.15) and 88.3% vs 73.9% (p=0.11), respectively]. After adjusting for prespecified risk factors, cilostazol administration was a negative predictor of Re-ISR. Conclusion: This small comparative study suggests that administering cilostazol for ISR lesions after femoropopliteal stenting reduces recurrent ISR.
GoodneyPPBeckAWNagleJet al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54–60.
2.
NorgrenLHiattWRDormandyJAet al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
3.
LairdJRKatzenBTScheinertDet al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–276.
4.
SchillingerMSabetiSDickPet al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.
5.
DindyalSKyriakidesC.A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat Cardiovasc Drug Discov. 2009;4:6–14.
6.
WarnerCJGreavesSWLarsonRJet al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014;59:1607–1614.
7.
IftikharOOliverosKTafurAJet al. Prevention of femoropopliteal in-stent restenosis with cilostazol: a meta-analysis. Angiology. 2016;67:549–555.
8.
RankeCCreutzigAAlexanderK.Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433–440.
9.
PatelMRConteMSCutlipDEet al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;10;65:931–941.
10.
TosakaASogaYIidaOet al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23.
11.
SogaYIidaOHiranoKet al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608–615.
12.
InoueTUchidaTSakumaMet al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004;44:1408–1414.
13.
MorishitaR.A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl. 2005;6:41–46.
14.
IidaOYokoiHSogaYet al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127:2307–2315.
15.
YasunagaKMaseK.Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung. 1985;35(7A):1189–1192.
DouglasJSJrHolmesDRJrKereiakesDJet al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826–2832.
18.
SogaYIidaOHiranoKet al. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79:541–548.
19.
IshiiHKumadaYToriyamaTet al. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients. Clin Ther. 2010;32:24–33.
20.
StabileEVirgaVSalemmeLet al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739–1742.
21.
KatsanosKGeislerBPGarnerAMet al. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open. 2016;6:e011245.
22.
DindyalSKyriakidesC.Regarding “Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia” [Letter]. J Vasc Surg. 2012;55:891; author reply 891–892.
23.
PrattCM.Analysis of the cilostazol safety database. Am J Cardiol. 2001;87(12A):28D–33D.
